title: Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo.
abstract: Arbidol, ethyl-6-bromo-4-[(dimethylamino)-methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-in dole-3-carboxylate hydrochloride monohydrate, is an antiviral chemical agent. In this report, we studied the antiviral activity of arbidol against a panel of human respiratory viruses, namely influenza A virus (FLU-A, A/PR/8/34 H1N1), respiratory syncytial virus (RSV), human rhinovirus type 14 (HRV 14), coxsackie virus B3 (CVB3) and adenovirus type 7 (AdV-7) in vitro in cell culture. Arbidol was found to present potent inhibitory activity against enveloped and non-enveloped RNA viruses, including FLU-A, RSV, HRV 14 and CVB3 when added before, during, or after viral infection, with 50% inhibitory concentration (IC50) ranging from 2.7 to 13.8 microg/ml. However, arbidol showed selective antiviral activity against AdV-7, a DNA virus, only when added after infection (therapeutic index (TI) = 5.5). Orally administered arbidol at 50 or 100 mg/kg/day beginning 24 h pre-virus exposure for 6 days significantly reduced mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Our results suggest that arbidol has the ability to elicit protective broad-spectrum antiviral activity against a number of human pathogenic respiratory viruses.
authors.affiliation: State Key Laboratory of Virology, Institute of Medical Virology, Wuhan University, Wuhan, P.R. China.
authors.forename: L
authors.initials: L
authors.lastname: Shi
authors.forename: H
authors.initials: H
authors.lastname: Xiong
authors.forename: J
authors.initials: J
authors.lastname: He
authors.forename: H
authors.initials: H
authors.lastname: Deng
authors.forename: Q
authors.initials: Q
authors.lastname: Li
authors.forename: Q
authors.initials: Q
authors.lastname: Zhong
authors.forename: W
authors.initials: W
authors.lastname: Hou
authors.forename: L
authors.initials: L
authors.lastname: Cheng
authors.forename: H
authors.initials: H
authors.lastname: Xiao
authors.forename: Z
authors.initials: Z
authors.lastname: Yang
mesh_terms: D000256:Adenoviridae / Q000187:drug effects*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D002460:Cell Line; D029822:Enterovirus B, Human / Q000187:drug effects; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D012328:RNA Viruses / Q000187:drug effects*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000401:mortality / Q000821:virology; D012229:Rhinovirus / Q000187:drug effects; D016896:Treatment Outcome; D014777:Virus Diseases / Q000188:drug therapy / Q000401:mortality / Q000821:virology; D013440:Sulfides
chemical_list: D000998:Antiviral Agents; D007211:Indoles; C086979:umifenovir; D013440:Sulfides